CSD500 Patents granted

Futura Medical PLC 09 May 2007 For immediate release 9 May 2007 Futura Medical Plc ('Futura' or 'the Company') CSD500 patents granted in 30 countries Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, announces that, in the run-up to the commercial launch of its novel condom CSD500, patents have been granted, or are proceeding to grant, in 30 consumer markets including the principal territories within Europe, the US and Canada. Futura has submitted patent applications internationally to protect its unique intellectual property in a total of 38 countries and expects to receive patent grants in all of these countries in due course. CSD500, which will be marketed by SSL International plc (SSL) as a Durex(R) branded condom, contains an erectogenic gel known as Zanifil(R) which will help healthy men maintain a firm erection whilst wearing the condom. Futura and SSL are currently preparing for the market launch of CSD500 which will follow the anticipated marketing authorisation within the EU in the fourth quarter of 2007. Futura will receive a milestone payment once marketing authorisation for CSD500 is granted within the EU, and royalty based payments from future sales of the condom. James Barder, Futura Medical's Chief Executive, said: 'We are delighted with the progress we have made with our patent applications as IP protection will underpin our revenue streams from CSD500 following the commercial launch of the product by our marketing partner SSL.' For further information: Futura Medical plc James Barder, Chief Executive Tel: +44 (0) 1483 685 670 mail to: james.barder@futuramedical.co.uk www.futuramedical.co.uk Canaccord Adams Tel: +44 (0) 20 7050 6500 Mark Ashurst Tyler Broda Media enquiries: Buchanan Communications Mark Court / Rebecca Dietrich Tel: +44 (0) 020 7466 5000 Notes Futura Medical plc Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups. Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.co.uk This information is provided by RNS The company news service from the London Stock Exchange